Archive Category: 10X Stocks Archive

Welcome back to 10X Stocks! As the name implies, our core goal is to identify and invest in the precious few stocks that are set to gain 1,000% or more during the next 1-3 years. The key word being invest … not trade.

You’re reading that headline right… Since March 26 — exactly one week prior to President Donald Trump’s “Liberation Day” tariff announcement — our 10X Stocks portfolio has beaten other market indexes by an incredible 18-to-1 margin.

Right now, portions of South Africa and Botswana are being pounded by unprecedented rainfalls… These monsoon-like downpours started all the way back in mid-February, persisting for weeks through one of the area’s most brutal rainy seasons ever recorded. The rainfall has been intense enough to flood whole areas, disrupt agriculture, and even impair mining operations across the countryside.

In last week’s update, I assured you that Hims & Hers Health (HIMS) was poised for a major breakout after finding support at the $25 level. It was one of many times I’ve reaffirmed my strong belief that the stock is still a “good buy” since I originally recommended it in August 2022 at less than $7 a share. Well, on Monday, shares of HIMS rocketed more than 30% higher on the announcement of a new deal with Novo Nordisk A/S (NOV), which will put Novo’s blockbuster drug Wegovy on Hims’ platform as early as this week.

Hims & Hers Health (HIMS) has been one of our best-performing holdings since I first added it to the 10X Stocks portfolio two-and-a-half years ago. But 2025 has dealt a vicious “one-two” punch to our favorite telehealth company, combining a declining stock market with the recent revocation of HIMS’ ability to offer GLP-1 weight loss drugs. The result has been a significant drawdown in HIMS’ share price, even though the stock is still up over 126% in the last year.